Drug-Induced Chronic Hepatitis

1982 ◽  
pp. 53-60
Author(s):  
Ralph Wright
Keyword(s):  
Chronic Hepatitis ◽  
Drug Induced

scholarly journals Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Shih Yea Sylvia Wu ◽  
Bridget Faire ◽  
Edward Gane
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Kidney Injury ◽  
Complete Recovery ◽  
Final Diagnosis ◽  
Community Acquired Pneumonia ◽  
Drug Induced ◽  
First Case ◽  
Life Threatening

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.

scholarly journals Scleromyxedema (Arndt - Gottron Syndrome) Developing Under Tenofovir Treatment for Hepatitis B: Unique Presentation in a Bulgarian Patient!

2019 ◽  
Vol 7 (5) ◽  
pp. 782-785 ◽  
Author(s):  
Ivanka Temelkova ◽  
James Patterson ◽  
Georgi Tchernev
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hepatitis Virus ◽  
Histological Study ◽  
Drug Induced ◽  
Systemic Involvement ◽  
First Case ◽  
The Face ◽  
Hepatitis B Treatment

BACKGROUND: Scleromyxedema, also referred to as the Arndt-Gottron (S-AG) syndrome or the systemic form of Lichen myxedematosus (LM), is a cutaneous mucinosis with a chronic course and high lethality from systemic involvement of other organs and systems. Interesting in several aspects is the association between scleromyxedema and viral hepatitis about: 1) hepatitis virus infection as a possible etiological factor for the development of scleromyxedema, 2) antiretroviral therapy for the treatment of hepatitis as a method of reversing scleromyxedema and 3) antiviral drugs as inducers of scleromyxedema. CASE REPORT: We present a 53-year old patient who for nine months had been on tenofovir disoproxil 245 mg (0-0-1) therapy for chronic hepatitis B. Three months after the start of antiviral therapy (i.e. for a period of 6 months), the patient observed swelling, itching and hardening of the skin on the face, ears and hands, which subsequently spread throughout the trunk. Subsequent histological study of a skin biopsy revealed changes of scleromyxedema at an advanced stage, though immunoelectrophoresis of serum and urine excluded the presence of paraproteinaemia or para proteinuria. Systemic antihistamine and topical corticosteroid therapy were instituted. Bone involvement with possible plasmacytoma was excluded, and a myelogram showed evidence of an erythroblastic reaction of bone marrow. CONCLUSION: We believe that drug-induced scleromyxedema is a rare but possible phenomenon. We describe the first case of tenofovir-induced scleromyxedema within the framework of chronic hepatitis B treatment.

Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis

2010 ◽  
Vol 61 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Wan Beom Park ◽  
Won Kim ◽  
Kook Lae Lee ◽  
Jae-Joon Yim ◽  
Moonsuk Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C

2011 ◽  
Vol 140 (5) ◽  
pp. S-951
Author(s):  
R Kenton Devine ◽  
Hejun Yuan ◽  
Mamta K. Jain ◽  
Corron M. Sanders ◽  
Nahid Attar ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Chronic Hepatitis C ◽  
Genomic Dna ◽  
Drug Induced ◽  
Human Genomic ◽  
Human Genomic Dna

scholarly journals Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir

2015 ◽  
Vol 45 (10) ◽  
pp. E156-E160 ◽  
Author(s):  
Akira Okajima ◽  
Kanji Yamaguchi ◽  
Hiroyoshi Taketani ◽  
Tasuku Hara ◽  
Hiroshi Ishiba ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Injury ◽  
Chronic Hepatitis C ◽  
Drug Induced ◽  
Drug Induced Liver Injury
Sign in / Sign up

Export Citation Format

Share Document